Navigation Links
Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:2/11/2013

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTC: AEMD), announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK:  www.retailinvestorconferences.com> red "register/ watch event now" button

Aethlon Medical's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system.  At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers.  For more information, please visit www.aethlonmedical.com.

About The Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system.  In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment.  Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens.  The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA. 

The Aethlon Hemopurifier® and Cancer

In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer.  Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance.  By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
2. Aethlon Medical Discloses CEO Interview
3. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
4. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
5. Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
6. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
7. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
8. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
9. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
10. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
11. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet talent ... an outdated healthcare executive resume. , “If you’re a healthcare executive open to new ... wondering if it’s as ready as you are for a new job search. I’ve ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. , ... MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron Live! ... to helping organizations maximize the benefits of mobility in their operations securely. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is ... been asked to present at the upcoming Aesthetic Meeting. Held in San Diego, at ... Drs. Furnas and Canales will lend their expertise to the Premier Global Hot Topics ...
Breaking Medicine News(10 mins):